FDA to fast track Mesoblast's cell therapy for heart failure
December 20, 2017 at 23:58 PM EST
Dec 21 (Reuters) - Australian drug developer Mesoblast Ltd said on Thursday the U.S. Food and Drug Administration would fast track the review of its cell therapy treatment for heart failure patients under a new designation rolled out last December.
